Group 1 - The company has not distributed cash dividends, issued bonus shares, or converted reserves into share capital during the reporting period [3] - There has been no change in the controlling shareholder or actual controller during the reporting period [5] - The company has no preferred shareholders or related holdings during the reporting period [5] Group 2 - All directors attended the board meeting to review the report [2] - The report does not include any non-standard audit opinions [3] - There are no significant matters reported during the period [5]

Group 1 - The company announced the approval of multiple proposals, including the "2025 Semi-Annual Report and its Summary" during the eighth meeting of the seventh Supervisory Board [2]

Core Viewpoint - The company announced the approval of multiple proposals, including the "2025 Semi-Annual Report and its Summary" during the 11th meeting of the 7th Board of Directors held on August 15 [2] Group 1 - The company held its 11th meeting of the 7th Board of Directors on August 15 [2] - The meeting resulted in the approval of the "2025 Semi-Annual Report and its Summary" among other proposals [2]

Group 1 - The company, Huayuan Bio, announced that its 11th meeting of the 7th board of directors was held on August 15, 2025, to discuss the revision of the company's articles of association and related documents [2] - For the year 2024, the revenue composition of Huayuan Bio was 65.08% from vitamins and 34.92% from the pharmaceutical manufacturing sector [2]

Group 1 - The company announced the extension of the expected operational dates for several investment projects without changing the implementation subject, location, or investment scale [2] - The projects affected include the annual production of 6,000 tons of Vitamin A powder, 20,000 tons of Vitamin E powder, 5,000 tons of Vitamin B6, 200 tons of Biotin, and 10,000 tons of L-Alanine (fermentation method) along with a biomanufacturing pilot base project [2]

（编辑 楚丽君） 证券日报网讯 8月15日晚间，花园生物发布公告称，公司于2025年8月15日召开了第七届董事会第十一 次会议及第七届监事会第八次会议，审议通过了《关于调整部分募投项目用途及新增募投项目的议 案》，同意公司调整向不特定对象发行可转换公司债券部分募集资金投资项目的用途并新增募投项目。 ...

Core Viewpoint - Garden Biologics reported a positive financial performance for the first half of 2025, with increases in revenue and net profit compared to the previous year [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 635 million yuan, representing a year-on-year increase of 5.86% [2] - The net profit attributable to shareholders was around 162 million yuan, showing a year-on-year growth of 13.67% [2] - Basic earnings per share were 0.3 yuan, which is a 15.38% increase compared to the same period last year [2]

格隆汇8月15日丨花园生物(300401.SZ)公布2025年半年度报告，上半年公司实现营业收入6.35亿元，同 比增长5.86%；归属于上市公司股东的净利润1.62亿元，同比增长13.67%；归属于上市公司股东的扣除 非经常性损益的净利润1.495亿元，同比增长37.36%；基本每股收益0.30元。 ...

Meeting Announcement - Zhejiang Huayuan Biopharmaceutical Co., Ltd. will hold the first bondholders' meeting for "Huayuan Convertible Bonds" on September 2, 2025 [1] - The meeting was approved by the company's 11th meeting of the 7th Board of Directors on August 15, 2025 [1] Meeting Participation - Bondholders registered with China Securities Depository and Clearing Corporation Limited as of August 26, 2025, can participate in the meeting either in person or via communication [2] - Proxy representation is allowed, and the proxy does not need to be a bondholder [2] Registration Details - Registration for the meeting will take place on August 29, 2025, from 9:00 AM to 11:30 AM and 1:00 PM to 5:00 PM at the company's securities department [2] - Specific documentation is required for both individual and institutional bondholders to register [2] Voting Procedures - Each bondholder has one vote per bond with a face value of RMB 100 [3] - Voting can be conducted in person or via mail, with specific deadlines for submission [4] Meeting Resolutions - Resolutions passed during the meeting will take effect immediately unless they require approval from relevant authorities [4] - Voting results will be binding on all bondholders, including those who did not attend the meeting [4]

Group 1 - The company Zhejiang Huayuan Biopharmaceutical Co., Ltd. has issued convertible bonds to unspecified investors, with a total amount of RMB 1.2 billion [2][3] - The bonds have a maturity of 6 years, with an annual interest rate that increases from 0.3% in the first year to 2.5% in the sixth year [4][5] - The initial conversion price for the bonds is set at RMB 15.19 per share, subject to adjustments based on various corporate actions [5][6] Group 2 - The funds raised from the bond issuance will be used for projects including the production of 6,000 tons of Vitamin A powder and 20,000 tons of Vitamin E powder, with a total investment of RMB 134.446 million [12][13] - The company plans to adjust the use of raised funds, reallocating some towards a new project for producing 1 billion solid dosage forms and 8 million injections, with a total investment of RMB 19.11 million [22][23] - The project aims to enhance the company's R&D and production capabilities, addressing the growing demand for high-quality pharmaceuticals in various therapeutic areas [23][24] Group 3 - The company has faced increased competition in the generic drug market, prompting a strategic shift in its investment focus [21][24] - The new project is expected to improve the company's production efficiency and meet international quality standards, ultimately benefiting patients [23][25] - The project is aligned with national policies promoting the development of innovative pharmaceuticals and aims to strengthen the company's market position [26][27]